VX-548 selectively inhibits NaV1.8, a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. Treatment with oral VX-548 resulted in a statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback